MEDITERA TIBBI MALZEMENAYI VE TICARET ASIST:MEDTR -0.93%79 Operating Margin % is 2.45% as of Mar. 2026, which is 87% below its 10-year median of 19.26. GuruFocus rates IST:MEDTR with a GF Score™ of 79/100 and a GF Value™ of ₺43.41 (Significantly Undervalued). The stock has 5 warning signs investors should review. Among 816 Medical Devices & Instruments companies, MEDITERA TIBBI MALZEMENAYI VE TICARET AS ranks worse than 50.37% on this metric.
IST:MEDTR'
s Operating Margin % Range Over the Past 10 Years
Min: 3.39 Med: 19.26 Max: 28.37
Current: 3.39
IST:MEDTR's Operating Margin % is ranked worse than 50.37% of 816
companies
in the Medical Devices & Instruments industry
Industry Median: 3.465
vs IST:MEDTR: 3.39
MEDITERA TIBBI MALZEMENAYI VE TICARET AS (IST:MEDTR) Operating Margin % Explanation
Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.
Be Aware
Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).
If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.
For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokias Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).
Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.
MEDITERA TIBBI MALZEMENAYI VE TICARET AS Operating Margin % Related Terms
MEDITERA TIBBI MALZEMENAYI VE TICARET AS Operating Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEDITERA TIBBI MALZEMENAYI VE TICARET AS Operating Margin % Chart
MEDITERA TIBBI MALZEMENAYI VE TICARET AS Annual Data
IST:MEDTR vs ABT, SYK, MDT: Operating Margin % Comparison
For the Medical Devices subindustry, MEDITERA TIBBI MALZEMENAYI VE TICARET AS's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MEDITERA TIBBI MALZEMENAYI VE TICARET AS Operating Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, MEDITERA TIBBI MALZEMENAYI VE TICARET AS's Operating Margin % distribution charts can be found below:
* The bar in red indicates where MEDITERA TIBBI MALZEMENAYI VE TICARET AS's Operating Margin % falls into.
MEDITERA TIBBI MALZEMENAYI VE TICARET AS Operating Margin % Calculation
Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEDITERA TIBBI MALZEMENAYI VE TICARET AS (IST:MEDTR) has a Operating Margin % of 2.45% as of Mar. 2026. Operating margin is the ratio of total operating income to net sales. View historical data on MEDITERA TIBBI MALZEMENAYI VE TICARET AS and its competitors. This is 87% below median its historical median of 19.26. Over the past decade, MEDITERA TIBBI MALZEMENAYI VE TICARET AS's Operating Margin % has ranged from 3.39 to 28.37. According to the industry distribution chart, MEDITERA TIBBI MALZEMENAYI VE TICARET AS ranks #411 out of 816 companies in the Medical Devices & Instruments industry, placing it in the top 50.4%.
Is MEDITERA TIBBI MALZEMENAYI VE TICARET AS's Operating Margin % too high?
MEDITERA TIBBI MALZEMENAYI VE TICARET AS's current Operating Margin % of 2.45% is 87% below median its 10-year median of 19.26. Over the past 10 years, this metric has ranged from a low of 3.39 to a high of 28.37. The Medical Devices & Instruments industry median Operating Margin % is 3.47. MEDITERA TIBBI MALZEMENAYI VE TICARET AS's value of 2.45% is 29.3% below this industry median. Based on the distribution chart, MEDITERA TIBBI MALZEMENAYI VE TICARET AS ranks #411 out of 816 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, MEDITERA TIBBI MALZEMENAYI VE TICARET AS has a GF Score™ of 79/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does MEDITERA TIBBI MALZEMENAYI VE TICARET AS's Operating Margin % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, MEDITERA TIBBI MALZEMENAYI VE TICARET AS ranks #411 out of 816 companies for Operating Margin %. This places MEDITERA TIBBI MALZEMENAYI VE TICARET AS in the lower half of its industry. The industry median Operating Margin % is 3.47. MEDITERA TIBBI MALZEMENAYI VE TICARET AS's value of 2.45% is 29.3% below this benchmark. Historically, MEDITERA TIBBI MALZEMENAYI VE TICARET AS's own Operating Margin % has ranged from 3.39 to 28.37 over the past decade. While the company's 10-year median is 19.26 vs. the industry median of 3.47, MEDITERA TIBBI MALZEMENAYI VE TICARET AS has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Margin % for a Medical Devices & Instruments company?
The median Operating Margin % among Medical Devices & Instruments companies is 3.47, based on 816 companies in the industry. Companies in the top quartile (top 25%) have a Operating Margin % significantly above this median, while those in the bottom quartile fall well below. However, Operating Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. MEDITERA TIBBI MALZEMENAYI VE TICARET AS's current Operating Margin % of 2.45% is 29.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Margin % mean?
A high Operating Margin % can signal that a stock is expensive relative to its fundamentals. Operating margin is the ratio of total operating income to net sales. View historical data on MEDITERA TIBBI MALZEMENAYI VE TICARET AS and its competitors. For the Medical Devices & Instruments industry, the median Operating Margin % is 3.47 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. MEDITERA TIBBI MALZEMENAYI VE TICARET AS's current Operating Margin % is 2.45%, which is 87% below median its own 10-year median of 19.26. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MEDITERA TIBBI MALZEMENAYI VE TICARET AS stock overvalued right now?
Based on GuruFocus' analysis, MEDITERA TIBBI MALZEMENAYI VE TICARET AS (IST:MEDTR) is currently considered Significantly Undervalued. The stock's GF Value™ is ₺43.41, compared to a current price of ₺29.90 — trading 31.1% below its estimated fair value. The current Operating Margin % is 2.45%, which is 87% below median its 10-year median of 19.26 and 29.3% below the Medical Devices & Instruments industry median of 3.47. MEDITERA TIBBI MALZEMENAYI VE TICARET AS's overall GF Score™ is 79/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Margin % calculated?
Operating Margin % is calculated from a company's financial statements. For MEDITERA TIBBI MALZEMENAYI VE TICARET AS (IST:MEDTR), the current Operating Margin % is 2.45% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is MEDITERA TIBBI MALZEMENAYI VE TICARET AS (IST:MEDTR) Overvalued in 2026?
Based on GuruFocus' analysis, MEDITERA TIBBI MALZEMENAYI VE TICARET AS stock appears to be undervalued.
The current stock price of ₺29.90 is trading 31.1% below its estimated GF Value™ of ₺43.41.
GuruFocus considers MEDITERA TIBBI MALZEMENAYI VE TICARET AS to be Significantly Undervalued.
Key valuation signals for IST:MEDTR:
Operating Margin %: 2.45% (87% below median its 10-year median of 19.26)
GF Value™: ₺43.41 vs. price of ₺29.90 (31.1% below fair value)
Industry Position: 29.3% below the Medical Devices & Instruments median (#411 of 816)
No single metric tells the full story. See the IST:MEDTR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
MEDITERA TIBBI MALZEMENAYI VE TICARET AS Business Description
MEDITERA TIBBI MALZEME SANAYI VE TICARET AS is engaged in the manufacture of anesthesia and intensive care circuits, the installation, operation, and design of oncology drug preparation and delivery systems, production, sales, and technical service of infusion pumps and sets, and the manufacture of biocidal products.
79GF Score
Get the complete analysis for IST:MEDTR
Operating Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IST:MEDTR has been successfully added to your 
